ISLB 2021 | Liquid biopsy: future directions for ctDNA in NSCLC
Chris Abbosh, MD, PhD, The Francis Crick Institute & Cancer Research UK & University College London Cancer Institute, London, UK, discusses future research directions of liquid biopsy and ctDNA for non-small cell lung cancer (NSCLC). Research questions include whether ctDNA can be used as a response biomarker and how ctDNA levels relate to long-term survival endpoints. Using ctDNA as a biomarker for minimal residual disease (MRD) is an exciting area of research, and future directions include developing faster and simpler assay procedures to help clinicians make faster treatment recommendations to patients. This interview took place at the International Society of Liquid Biopsy (ISLB) 2021 Virtual Meeting.
Disclosures
Astrazeneca: Current Astrazeneca fellow, member of global study team managing MERMAID studies, speaker fees, advisory board.
University College London: Patents in MRD detection [Method of detecting tumour recurrence, methods for lung cancer detection]
